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There are adaptive T-cell and antibody autoimmune responses to
myelin-derived peptides in multiple sclerosis (MS) and to aquaporin-
4 (AQP4) in neuromyelitis optica spectrum disorders (NMOSDs).
Strategies aimed at antigen-specific tolerance to these autoantigens
are thus indicated for these diseases. One approach involves induc-
tion of tolerance with engineered dendritic cells (tolDCs) loaded
with specific antigens. We conducted an in-human phase 1b clinical
trial testing increasing concentrations of autologous tolDCs loaded
with peptides from various myelin proteins and from AQP4. We
tested this approach in 12 patients, 8 with MS and 4 with NMOSD.
The primary end point was the safety and tolerability, while sec-
ondary end points were clinical outcomes (relapses and disability),
imaging (MRI and optical coherence tomography), and immunolog-
ical responses. Therapy with tolDCs was well tolerated, without
serious adverse events and with no therapy-related reactions. Pa-
tients remained stable clinically in terms of relapse, disability, and in
various measurements using imaging. We observed a significant in-
crease in the production of IL-10 levels in PBMCs stimulated with the
peptides as well as an increase in the frequency of a regulatory T cell,
known as Tr1, by week 12 of follow-up. In this phase 1b trial, we
concluded that the i.v. administration of peptide-loaded dendritic
cells is safe and feasible. Elicitation of specific IL-10 production by
peptide-specific T cells in MS and NMOSD patients indicates that a
key element in antigen specific tolerance is activated with this ap-
proach. The results warrant further clinical testing in larger trials.
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Antigen-specific immunotherapies for autoimmune diseasesaim to restore peripheral immune tolerance for pathogenic
adaptive T- and B-cell responses without dampening the overall
immune surveillance against microbes and cancer (1). Therefore,
by using a highly selective approach, the safety and efficacy of
immunotherapies should be enhanced. Several approaches have
been tested aimed to restore immune tolerance, including peptide-
based tolerance vaccines (either oral, i.v., intradermal, or i.m.),
altered peptide ligands, DNA vaccination, or cell-based tolerance
[T-cell vaccines, leukocytes coupled with peptides, mesenchymal
stem cells, regulatory macrophages, T or B cells, or tolerogenic
dendritic cells (tolDCs) (1–3)]. A probabilistic model of the
immune system states that immune responses (including auto-
immune responses) require a minimum number of MHC–peptide–
T cell receptor complexes to be formed (4), providing support for
testing antigen-specific tolerance based on increasing the exposure
of self-antigens within an antiinflammatory environment, which can
be provided by tolDCs (5). The induction of tolDCs is an approach
tested for antigen-specific tolerance in autoimmune diseases such
as rheumatoid arthritis, type 1 diabetes, and Crohn’s disease.
These trials with tolDCs have shown satisfactory safety and some
evidence of immune tolerance (6–10).
Genetic and immunological studies support the involvement of
myelin-specific immune responses in the pathogenesis of multiple
sclerosis (MS) (1). Even if the target antigen remains unknown, by
promoting immune tolerogenic responses in adaptive immune
cells that migrate to the inflamed CNS, an amelioration of the
inflammatory process can be achieved (2). Previous trials of tol-
erance with myelin peptides in MS have been shown to be safe
and that the peptides are capable of induction of immunomodu-
latory responses (11).
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Neuromyelitis optica spectrum disorders (NMOSDs) represent an
excellent opportunity for testing immune tolerance protocols. In
NMOSD, the target autoantigen, is well identified, the aquaporin-4
(AQP4) (12, 13), and up to 80% of the patients have anti-AQP4
antibodies in the blood or the cerebrospinal fluid. All NMOSD pa-
tients in this trial were required to have anti-AQP4 antibodies.
In this study, we tested the safety of CNS peptide-loaded
tolDC therapy and searched for signs of efficacy and markers of
immune tolerance in patients with MS and NMOSD. We focused
on tolDCs based on our previous experience in Crohn’s disease
for which tolDCs showed excellent safety and signs of clinical
efficacy (5, 9). Moreover, we combined in the same protocol
patients with either MS or NMOSD to obtain evidence for the
safety of tolerance induction with a diversity of CNS-related pep-
tides. The use of a battery of tolDCs for different peptides would
allow a potential approach for a broader swathe of patients.
Materials and Methods
Ethical Statement. The protocol was reviewed and approved by the Ethics
Committee of the Hospital Clinic of Barcelona and the Spanish Agency of
Drugs and Sanitary Products (SI Appendix). All procedures were done fol-
lowing the rules of the Declaration of Helsinki Guidelines. The trial is reg-
istered under European Clinical Trials Database no. 2013-005165-39 and
National Clinical Trial no. NCT02283671. All patients signed a written in-
formed consent before inclusion in the study.
Study Design. The study was an open-label, single-center, multiple ascending-
dose phase 1b clinical trial of 3 mo of follow-up (SI Appendix, Fig. S1). We
included a total of 12 patients: 8 with MS and 4 with NMOSD. The trial was
performed at the Hospital Clinic of the University of Barcelona, and patient
recruitment was performed between September 2015 and July 2017.
Participants were assigned to four blocks of three patients each (two MS
and one NMOSD per block), and they were consecutively included once the
safety of the previous cohort of patients was confirmed based on the absence
of serious adverse events in that previous dose after 3 mo of follow-up.
Intravenous administration of the cells was done slowly over 1 h, after
resuspension of the product in physiological saline solution. The cell dose
escalation was 50 × 106, 100 × 106, 150 × 106, and 300 × 106 tolDCs in total,
separated in three independent doses administered every 2 wk. The last
group did not receive the programmed doses [300 million tolDCs (100 mil-
lion for each dose)] due to a technical limitation to obtain the required
number of cells on the leukapheresis, and for this reason, they received
the maximum yield of the cultures, always above 150 million cells in total.
We conducted 1-h monitoring after the administration for safety purposes.
Cell viability, sterility, purity, and functionality of the final product were
evaluated and registered for each patient and procedure, as previously
described (9).
Abaseline visitwas conducted afterpatients fulfilled the inclusion criteria and
signed the informed consent. Brain MRI and an optical coherence tomography
(OCT) were performed at baseline and by week 12, as previously described (14).
Blood tests for analyses and immunological assessment were done every 2 wk.
The neurological examination included the Expanded Disability Status Scale
(EDSS) (15) and the Multiple Sclerosis Functional Composite (MSFC) (16), which
were done at baseline and by week 12. Quality of life was assessed with the
Short Form-36 questionnaire at baseline and end of follow-up (17).
Primary and Secondary End Points. The primary end point of the study was to
evaluate the safety and tolerability of the treatment. Safety and tolerability
were determined by the number and severity of adverse effects (AEs) related
to tolDC administration using the MedDRA dictionary (https://www.meddra.
org). Secondary end points were (i) assessment of clinical efficacy in terms of
relapse rate and changes in the disability scales (EDSS and MSFC): (a)
remaining relapse-free by week 12; (b) change on EDSS from baseline to
week 12; and (c) change of MSFC from baseline to week 12; (ii) assessment of
imaging efficacy: (a) number of new gadolinium-enhancing lesions at week
12; (b) number of new/enlarging T2-weighted fluid-attenuated inversion
recovery (T2-FLAIR) lesions at week 12; and (c) changes in peripapillary ret-
inal nerve fiber layer and macular volume (MV) from baseline to week 12;
and (iii) changes in the immune responses (cytokine production and cell
proliferation) to peptides and differential immune cell counts at week 12.
Inclusion and Exclusion Criteria. Inclusion criteria were (i) patients diagnosed
with MS based on the 2010 McDonald criteria (18) or NMOSD with anti-
AQP4 antibodies based on Wingerchuk criteria (19); (ii) disease duration
≥1 y; (iii) age between 18 and 65 y; and (iv) EDSS between 3 and 8.5. All
NMOSD patients were required to have anti-AQP4 antibodies. Excluding
criteria were (i) presence of a relapse or use of steroids the month before the
screening; (ii) use of immunomodulatory/immunosuppressive therapy in the
case of MS in the last 12 mo, but NMOSD patients were allowed to maintain
their immunomodulatory treatment stable for 6 mo for ethical requirements
(20); (iii) impossibility to perform brain MRI with gadolinium contrast, severe
systemic diseases, or history of personal cancer or hereditary familial cancer;
(iv) impossibility to proceed to the leukapheresis (e.g., absence of peripheral
vein access); (v) participation in other experimental studies within the pre-
vious 3 mo; and (vi) pregnant or breastfeeding women.
Generation of Tolerogenic Dendritic Cells. Autologous monocyte-derived den-
dritic cells (DCs) were obtained by leukapheresis (Amicus; Fresenius Kabi), and
tolDCs were generated under good manufacturing practice (GMP) conditions
by conditioning monocyte-derived DCs, as previously described (9, 21), and
reported following minimum information about tolerogenic antigen-
presenting cells criteria (22). Briefly, monocytes were cultured in the pres-
ence of 500 IU (international units)/mL of IL-4 and 800 IU/mL of GM-CSF
(Miltenyi Biotec) during 7 d in X-VIVO-15 (BioWhittaker; Lonza) supple-
mented with 2% autologous serum. At day 3, fresh medium and cytokines
were added; furthermore, 10−6 M dexamethasone (Merck) was added to the
cells to induce the tolerogenic phenotype. At day 6, to boost peptide-specific
DC tolerogenic properties, a mixture of cytokines including IL-1β, IL-6, TNF-α,
and prostaglandin E2 (Miltenyi Biotec), as well as the immunogenic peptides
(SI Appendix, Table S1), were added for 24 h and washed before administra-
tion. DCs from MS patients were stimulated with the seven myelin peptides
from myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligo-
dendrocyte glycoprotein (MOG) (described in ref. 11), and DCs from NMOSD
patients were stimulated with the seven myelin peptides plus the T-cell im-
munogenic peptide from AQP4, as described in ref. 23. The peptides MBP13–32
(MBP1), MBP83–99 (MBP2), MBP11–129 (MBP3), MBP146–170 (MBP4), MOG1–20
(MOG1), MOG35–55 (MOG2), PLP139–154 (PLP1), and AQP463–76 were produced in
GMP conditions (Hemmo Pharmaceuticals) and added at 5 μM to the cultures.
After sterility testing and phenotype and purity characterization, tolDCs were
administered by i.v. injection. Progressively increasing total DCs doses were
injected in all of the cohorts (50 × 106, 100 × 106, 150 × 106, and 300 × 106 DCs)
divided into three consecutive doses at weeks 0, 2, and 4 (SI Appendix, Fig. S1).
Characterization of tolDC Phenotype and Cytokine Production. tolDCs from
each patient were characterized assessing for their phenotype, cytokine pro-
duction, and immunogenicity. As depicted in SI Appendix, Fig. S2A, clinical
grade-produced tolDCs presented semimature phenotype (lower expression of
maturation marker CD83 and MHCII compared with mature DCs) and increased
expression of the glucocorticoid-induced receptor MERTK, which was described
as a marker for tolDCs (24). Moreover, clinical grade-generated tolDCs pro-
duced higher amounts of the immunosuppressive cytokine IL-10 at baseline and
after LPS challenge compared with mature immunogenic DCs (SI Appendix, Fig.
S2B). Neither IL-12 nor IL-23 was produced by tolDCs (data not shown).
MRI. MRI examinations were performed on a 3T Siemens Trio MRI scanner at
the Hospital Clinic of the University of Barcelona, as previously described (14).
Scans were performed at baseline and at week 12 of follow-up. A 1.5T MRI
scanner was used for patient MS01 because she has an implanted abdominal
Significance
Application of antigen-specific immune tolerance in autoimmune
disease is a long-sought goal. We studied diseases with abundant
information on the autoimmune target: in multiple sclerosis (MS),
various myelin antigens are known targets of T cells and anti-
bodies, whereas in neuromyelitis optica (NMO), the aquaporin-
4 channel is attacked by T cells and antibodies. We testedwhether
engineered dendritic cells might induce a tolerogenic immune
response in these two conditions. In this in-human clinical study,
individual regulatory T cells, secreting IL-10, a key tolerogenic cy-
tokine, were detected after treatment. These results might lead to
more extensive trials with this approach in autoimmune condi-
tions where the antigenic target has been identified, including
MS, NMO, myasthenia gravis, and Graves disease.






















stimulator, which prevented the use of a high-field scanner. The sequences
obtained were T1-magnetization prepared rapid gradient echo before and
spin echo after gadolinium administration and T2-FLAIR sequences as
previously described (14).
OCT. OCT was performed using a spectral domain device (Spectralis; Hei-
delberg Engineering), as previously described (14), and performed before
therapy initiation and by week 12 follow-up. We calculated the thickness of
the peripapillary retinal nerve fiber layer thickness and MV from each eye at
baseline and week 12 following criteria as previously described (25).
Flow Cytometry Analysis. Different immune cell subsets frequencies were
analyzed from the patient’s peripheral blood mononuclear cells (PBMCs).
The antibody panels for flow cytometry were (i) PBMC subtypes CD3, CD4,
CD9, CD14, CD19, and CD56; (ii) T-lymphocyte subpopulations; (iii) Treg
subsets: natural Tregs (CD4+CD25+Foxp3+) and Tr1 (CD4+IL−10+); (iv) T-
helper subpopulations: Th1 (CD4+IFN-γ+), Th2 (CD4+IL-4+), and Th17 (CD4+
IL-17+); (v) CD4 and CD8 GM-CSF “encephalitogenic” T cells; and (vi) T-cell
subtypes by activation memory phenotype: CD4+CD161+ and CD8+CD161+.
The list of antibodies and panels is shown in SI Appendix, Table S2. Cells were
analyzed in a Canto cytometer and analyzed using the FACSDiva software.
Antigen-Specific Proliferation. PBMCs 2 × 105 were cultured in a 96-well round
plate in 200 μL of X-VIVO 15 medium (BioWhittaker; Lonza) supplemented
with 2% AB human serum (Sigma-Aldrich). Cells were stimulated with each
individual peptide at 5 μM or a pool of all peptides in triplicates for each
condition for 6 d. Cells were cultured for 6 d at 37 °C and 5% CO2. On day 6,
50 μL of supernatant from each condition was collected and frozen at −20 °C.
Then, 1 μCi of [3H]thymidine was added to the culture for 12–16 h at 37 °C and
5% CO2. Afterward, the plates were frozen until being read. Thymidine in-
corporation was measured using a Wallac Beta Liquid Scintillation counter
(Perkin-Elmer). Measurements were obtained as cpm and calculated the
stimulation index (SI) as cpm peptides/cpm unstimulated (26).
ELISA. Supernatant from PBMCs cultures was collected after 6 d of stimulation
and analyzed by ELISA the production of IFN‐γ (BD OptEIA; BD Biosciences)
and IL‐10 (eBioscience), following the manufacturer’s guidelines. Results are
reported as pg/mL.
Enzyme-Linked Immunospot Assay. Enzyme-linked immunospot (ELISPOT)
assays for IL-10, IFN‐γ, IL-17, and IL-4 (U-CyTech) were performed after 2-
d stimulation of PBMCs with each individual peptide, according to the
manufacturer’s guidelines. Peptides were added as 1:10 dilution of the 5 mM
peptide stimulus, and 2 μL of each peptide was added to each well. Results are
reported as the number of cells with spots for a given cytokine, as described in
refs. 27 and 28. Stimuli well spot number = (mean of three wells for each
stimulus) − (mean of three wells of negative control) for 200,000 PBMCs per well.
HLA-DRB1* Typing. DNA HLA-DRB1* typing was conducted at the Depart-
ment of Immunology of our center using high-resolution PCR.
Genomic DNA was collected from the cell pellets after in vitro assays using
a QIAmp DNABlood Mini Kit (QIAGEN), following the manufacturer’s in-
structions, and stored at −20 °C. Allelic variants were genotyped using the
TaqMan SNP Genotyping Assay (Applied Biosystems). The specific primers
and FAM and VIC dye-labeled probes used were designed by the Applied
Biosystems assay-on-demand service.
Statistical Analysis. All data analysis was conducted based on the intent‐to‐treat
principle, except where stated otherwise. Variables were tested for normality
using the Kolmogorov–Smirnoff test. Differences in immunological assays from
baseline to week 12 were assessed with the Wilcoxon test due to biological
variability and the small sample size, preventing the assumption of normality.
Changes in cytokines from baseline to week 12 were tested using Wilcoxon test
by pooling all doses together (analysis for each dose or a dose–effect analysis
was not possible due to the small sample size). All analyses were done in R
software. The sample sizes for this dose escalation trial (three patients per dose)
were chosen to detect major intolerability signals. Consistent with the design of
phase 1 trials, this study was underpowered to elucidate clinical efficacy.
Results
We included 12 patients in the trial, 8 with MS and 4 with
NMOSD (all of them testing positive for anti-AQP4 antibodies, as
required by the inclusion criteria). The summary of the demo-
graphic and clinical data appears in Table 1. All patients received at
least one dose, and all patients except one received the three doses
and completed the 12-wk assessment. All patients included com-
pleted the 24-wk safety assessment. Patient NMO03 withdrew from
the study after the first dose of tolDCs for personal reasons (no
safety concern) but completed the safety follow-up.
Safety. During the 24-wk follow-up, 16 nonsevere AEs were
reported. All AEs were considered unrelated to therapy (Table
2). Half of the study population reached the 2-y long-term safety
milestone, and there were two severe AEs not related to the
therapy (MS01 and NMO01 had elected surgeries). Additionally,
we did not observe any clinically meaningful changes in vital
signs (temperature, blood pressure, heart rate), blood chemistry,
or blood cell counts at any time after tolDC administration.
Efficacy and Clinical Follow-Up. All patients remained clinically
stable in terms of relapses and disability worsening after 24 wk of
follow-up. Similarly, no changes were observed in quality of life
(Table 3). All patients included in the study (exception of NMO03)
completed the MRI and OCT assessments. Of the 12 patients
treated with tolDCs, 2 MS patients (MS06 and MS08) showed
one new T2 lesion in the MRI by week 12, but none of them
showed gadolinium-enhancing lesions at any time. We did not
Table 1. Demographic and clinical variables of the cohort
Patient ID Sex Age, y MS subtype Duration, y EDSS Previous DMD Concomitant DMD HLA DRB1
MS01 F 48 SPMS 14.79 5.0 MP NA *0101*0301
MS02 F 50 SPMS 9.67 6.0 IFN-β1a s.c. NA NA
MS03 M 27 PPMS 6.6 6.0 GA NA NA
MS04 F 57 PPMS 4.29 5.5 NA NA *1501*1301
MS05 M 40 SPMS 8.18 6.5 GA, IFN-β1a s.c. NA *0701*1001
MS06 M 57 SPMS 29.29 6.0 IFN-β1a i.m. NA *1104*1301
IFN-β1a s.c.
MS07 F 56 PPMS 7.46 6.5 NA NA *0102*0404
MS08 M 59 RRMS 1.81 6.0 GA NA *0101*1101
NMO01 M 38 NA 3.37 3.5 AZA, RTX, IFN-β1a s.c. RTX *03*13
NMO02 F 39 NA 21.91 6.0 AZA, RTX, PDN, IVIG, MTX MMF NA
NMO03 F 40 NA 3.22 4.5 RTX, MP RTX *0404*1001
NMO04 F 43 NA 8.47 5.0 RTX, CP, CyA, IVIG, MP RTX *0301*1101
AZA, azathioprine; CP, cyclophosphamide; CyA, cyclosporine A; F, female; GA, glatiramer acetate; IVIG, i.v. immunoglobulins; M, male; MMF, mycophe-
nolate mofetil; MP, methylprednisolone; MTX, mitoxantrone; NA, not available; PDN, prednisone; PPMS, primary-progressive multiple sclerosis; RRMS,
relapsing-remitting multiple sclerosis; RTX, rituximab; SPMS, secondary-progressive multiple sclerosis.
































observe significant changes in retinal thicknesses measured by
OCT (SI Appendix, Table S3).
Immunological Responses After tolDC Therapy. First, we evaluated
changes in the antigen-specific cell proliferation induced by tolDCs
by assessing [3H]thymidine incorporation in response to each pep-
tide or the pool of peptides. We did not find significant differences
on T-cell proliferation by week 12 after treatment for any of the
peptides compared with baseline, although we found a trend for
decreased proliferation in response to the AQP4 peptide by week
12 in NMOSD-treated patients (P = 0.067) (Fig. 1).
Second, we evaluated changes in cytokine secretion in response
to specific peptide stimulation in PBMC culture supernatants by
ELISA (INF-γ and IL-10) and in cultures by ELISPOT (IFN-γ,
IL-17, IL-4, and IL-10). We found a significant increase of IL-10
production by week 12 compared with baseline for all myelin
peptides (except MBP1) in patients with MS as well as for AQP4
in patients with NMOSD (Fig. 2). IL-10 production has been
previously described as associated with the induction of Tr1 cells
by tolDCs (5, 29). Regarding changes in cytokine production by
ELISPOT, we did not find significant differences for any of the
cytokines analyzed at the group level (Fig. 3).
Finally, we assessed whether tolDC therapy induced changes in
peripheral immune cell subset frequencies from baseline to week
12 after, including CD4 (Th1, Th2, Th17, naïve vs. memory cells,
GM-CSF–expressing cells), Treg (natural Treg and Tr1), CD8,
monocytes (CD14), B cells (CD19), and NK (CD56) cells, with or
without memory phenotype (CD161). We observed an upward
trend in the frequency of Tr1 cells (CD4+IL-10+; P = 0.14) and a
significant decrease in memory CD8 (CD8+CD161+; P = 0.021),
NK cells [CD56+CD161+ (P = 0.012) and CD14+CD56+ (P =
0.041)] in MS patients by week 12 compared with baseline, while the
remaining subpopulations did not show significant changes (Fig. 4).
Discussion
In this trial, we have shown feasibility and safety of treating
patients with MS and NMOSD with tolDCs loaded with either
myelin antigens or AQP4 antigens at the highest dose of feasible
Table 2. Adverse events during the study
Patient ID AE Severity
Relation with
the study drug Time to AEs, wk
Recovery of AEs
by week 12
MS01 Fatigue Mild Not related 1 Complete
MS01 Headache Mild Possibly related 1 Complete
MS01 Herpes labialis Mild Not related 4 Complete
MS01 Sensitive fluctuant symptoms Mild Not related 8 Persist
MS01 Instability Mild Not related 12 Complete
MS02 None
MS03 None
MS04 Casual fall and headache Severe Not related 8 Complete
MS04 Melena with treatment for
Helicobacter pylori (OCA7)
Severe Not related 12 Complete
MS05 None
MS06 Fatigue Mild Not related 1 Complete
MS07 Pain in left leg Mild Possibly related 2 Complete
MS07 Back pain Mild Not related 4 Complete
MS08 Cold Mild Possibly related 4 Complete
MS08 Fatigue Mild Not related 6 Persist
NMO01 Left leg pain Mild Possibly related 4 Complete
NMO01 Back pain Severe Not related 6 Persist
NMO02 None
NMO03 Palpitations Mild Possibly related 2 Complete
NMO03 Influenza Mild Possibly related 2 Complete
NMO04 None
Table 3. Disability assessed with the EDSS and MSFC from baseline to week 12
Patient
ID













9HPT PASAT3 MSFC EDSS
MS01 5.0 8.670 21.850 20.930 21.390 40 −0.422 4.0 9.650 19.500 20.600 20.050 57 −0.160 5.5
MS02 6.0 31.065 NA 25.365 25.365 5 0.943 6.0 41.450 120.540 22.700 71.620 60 1.662 6.0
MS03 6.0 12.035 50.560 NA 50.560 14 0.263 6.0 11.845 42.710 NA 42.710 30 −0.399 6.0
MS04 5.5 7.400 25.030 24.855 24.943 48 −0.148 5.5 7.425 31.125 30.040 30.583 57 −0.003 5.5
MS05 6.5 11.940 27.230 21.760 24.495 39 −0.205 6.5 13.000 30.815 23.620 27.218 46 −0.243 6.5
MS06 6.0 16.865 25.265 26.170 25.718 18 −0.453 6.0 10.500 25.300 26.500 25.900 28 −0.816 6.0
MS07 6.5 32.100 22.400 22.750 22.575 37 0.398 6.5 43.350 20.415 23.370 21.893 48 0.395 6.5
MS08 6.0 13.270 24.090 22.785 23.438 56 0.184 6.0 9.540 19.985 20.610 20.298 55 −0.213 6.0
NMO01 3.5 4.540 18.790 19.825 19.308 58 −0.247 3.5 4.795 18.705 20.535 19.620 59 −0.225 3.5
NMO02 6.0 8.725 22.565 23.180 22.873 39 −0.384 6.0 NA NA NA NA NA NA 6.0
NMO03 4.5 7.050 35.205 34.685 34.945 58 0.459 4.5 NA NA NA NA NA NA 4.5
NMO04 5.0 4.835 22.925 22.935 22.930 45 −0.387 5.0 NA NA NA NA NA NA 5.0
9HPT, nine hole-peg test; NA, not available; PASAT3, paced auditory serial addition test 3 seconds; T25FW, timed 25 feet walking.






















cells. Considering previous findings reporting reactivation of MS
activity after altered ligand peptide therapy (30), it is important
to highlight that therapy using tolDCs loaded with myelin pep-
tide was safe. The design of the study combined patients with MS
and NMOSD, treating both groups for tolerance induction with
seven myelin peptides, while adding for patients with NMOSD, the
combination of the AQP4 peptide plus the seven myelin peptides in
the tolerizing regimen. This design allowed leveraging treatments
for both conditions, with a constellation of different myelin anti-
gens, and supplementing the regimen for patients with NMOSD by
adding a peptide from AQP4. This allowed us to obtain safety data
as a proof of concept for future antigen-tolerance induction clinical
trials for both diseases. The trial was not powered for probing ef-
ficacy at the clinical level or at the imaging level, and for this reason,
no conclusions in terms of efficacy should be raised. Finally, the
immunological assessment revealed the induction of Tr1 cells pro-
ducing high levels of IL-10, as it has been described in previous
tolDCs trials (5, 29).
Therefore, we obtained evidence that tolDC therapy induces
peptide-specific tolerance by promoting the adaptive regulatory
T-cell function. Considering that Tr1 function is impaired in MS
(31), augmenting Tr1 function by tolDCs may contribute to re-
storing peripheral immune tolerance in patients with autoim-
mune diseases (32–34). Future trials powered to show clinical
efficacy would clarify whether the augmentation of the Tr1
response could modify the disease course in MS or NMOSD.
A
B
Fig. 1. Peptide-specific T-cell proliferation assays at baseline and week 12. MBP13–32, MBP83–99, MBP11–129, MBP146–170, MOG1–20, MOG35–55, PLP139–154, and
AQP463–76–specific T-cell responses, at baseline (before treatment) and 12 wk after tolDC treatment in patients with MS (A) or NMO (B), are shown. Pro-
liferative responses were measured by [3H]thymidine incorporation assay. Graphs (y axis) represent the SI.
































Indeed, NMOSD is becoming a promising candidate as a disease
that is optimal for testing immune tolerization, considering that the
target antigen is well known (AQP4) for this condition. The target
antigen AQP4 is actually part of the criteria for making a diagnosis of
this disease, making it both a “biomarker” and a target for therapy. In
addition, the clinical severity of NMOSD makes a case for de-
velopment of new therapies that are effective and safe. Targeting
the major pathologic immune response seems a compelling
strategy.
The improved knowledge and fine mapping of AQP4 epitopes
and associated HLA types should allow the design of specific
tolDC protocols as a path for personalized medicine. Indeed, the
fact that in our trial, the combination of peptides from different
antigens was well tolerated and induced Tr1 cells, suggests that a
pool of AQP4 peptides in different HLA class II contexts might
achieve even better results in NMOSD, than those so far seen
with one AQP4 epitope.
Regulatory DCs or tolDCs have shown the ability to dampen the
immune response and restore cell tolerance in animal models of
autoimmune diseases as well as in humans (3, 5, 35–37). TolDCs can
be generated in vitro by promoting its differentiation with GM-CSF
and IL-4 and inducing the regulatory phenotype with several stimuli
such as IL-10, TGF-β, vitamin D3, prostaglandin E2 or dexameth-
asone among others (35). tolDCs generated with dexamethasone
A
B
Fig. 2. Peptide-specific cytokine detection at baseline and week 12. Cytokine levels were measured by ELISA in the supernatant of PBMC cultures at each
time point and stimulated in vitro with the given peptide for 6 d. (A) IL-10 was significantly increased by week 12 in response to MBP2 (P = 0.028), MBP3 (P =
0.18), MBP4 (P = 0.43), PLP (P = 0.18), MOG1 (P = 0.025) and showed a trend for MOG2 (P = 0.69) and AQP4 (P = 0.063) but not for MBP1 (P = 0.465). (B) IFN-γ
levels were not significantly different between time points for any of the peptides.
A B
C D
Fig. 3. Peptide-specific ELISPOT assays at baseline and week 12. The frequency of T cells producing IL-10 (A), IFNγ (B), IL-17 (C), or IL-4 (D) in response to
peptides was analyzed in PBMC cultures at each time point and stimulated in vitro with the given peptide for 2 d.






















and other stimuli have a stable phenotype, high expression of HLA
class II molecules, intermediate expression of the costimulatory
molecules CD80 and CD86, low expression of CD40, express high
levels of IL-10 and TGF-β, and low levels of IL-12, IL-23, and TNF-
α, overall conferring a low capacity to stimulate T cells, with the
capacity to tolerize them (3, 35). Specifically, tolDCs induced with
dexamethasone have a low expression of CD1a and CD14, and they
express CD209 (34), which has been associated with the increase of
Treg cells in patients with Crohn’s disease (9).
Regarding the migratory capacity of DCs, in vivo imaging of
pulsed tolDCs in the experimental autoimmune encephalomy-
elitis model showed that these cells reached the liver and the
spleen at 24 h after i.v. injection, and in smaller amounts the
lymph nodes, thymus, and bone marrow, and remained stable for
7 d (38). Although it is unknown whether tolDCs are able to
migrate to the inflamed CNS in MS and NMOSD, the migration
to primary and secondary lymphoid organs suggest they can
modulate the peripheral immune response in such lymphoid
organs and alter the autoimmune attack to the brain. Regarding
the mechanism by which tolDCs exert their tolerogenic effects,
they may include contact-dependent mechanisms [e.g., PD-L1,
Fas-ligand, ICOS-ligand, Ig-like transcript-2 (ILT-2), ILT-3,
ILT4, HLA-G, and others] or contact-independent mechanisms
such as immunomodulatory cytokines (e.g., IL-10 and TGF-β) or
enzymes that generate immunomodulatory molecules or related
to nutrient deprivation (e.g., IDO, heme-oxygenase-1, iNOS, and
arginase 1), all mainly mediated by regulatory cells (3). In this
study, we have obtained evidence for the induction of IL-10 and
Tr1 responses in patients with MS or NMO treated with tolDCs.
Considering the critical role of DCs in the induction and
maintenance of central and peripheral tolerance, clinical-grade
human tolDCs have been tested in phase 1b clinical trials in type
1 diabetes, rheumatoid arthritis, and Crohn’s disease with evi-
dence for feasibility and safety (6–9). Most of the trials have
shown as the main immunological effect an increase in regula-
tory cells and their related cytokines (10), in agreement with our
finding of increased IL-10 production and frequency of Tr1 cells.
The search for immune-tolerance therapies or antigen-specific
vaccination to treat autoimmune diseases such as MS or
NMOSD is based on the need of more selective immunother-
apies designed to restore self-tolerance without causing general
immune suppression (1). The probabilistic model of the immune
system states that the outcome of the immune response is based
on the probability of presenting a given antigen in the appro-
priate context (pro- or antiinflammatory), showing a remarkable
robustness in the preference for pathogen targeted responses
compared with autoimmune responses (4). Considering that the
immune system exhibits the remarkable ability to detect sudden
increases in the abundance of self-antigens, this model provides a
framework for testing antigen-specific tolerance induction based
in the exposition of a higher than normal dose of self-antigens
[“the 100-fold increase in effective abundance” proposed in the
model (4)] within an antiinflammatory environment provided by
the tolDCs (5).
Fig. 4. Immune-cell subset analysis by flow cytometry at baseline and week 12. Percentage of cells (means ± SEM) at baseline and 12 wk after treatment:
CD4+, CD8+, B cells (CD19+), NK cells (CD56+), encephalitogenic cells (CD4+GM−CSF+ and CD8+GM−CSF+), Th1 (CD4+IFN-γ+), Th2 (CD4+IL-4+), Th17 (CD4+IL-17+),
Treg (CD4+CD25+Foxp3+), and Tr1 (CD4+IL-10+).
































In the case of MS, the target antigen is not known yet, although
proteins within the myelin sheath, such as MBP, MOG, and PLP,
are important targets of the autoreactive immune response (30,
39–41). To develop antigen-specific tolerance for MS, several
myelin immunodominant peptides have been identified ex vivo
from patients with MS (41, 42) and tested in clinical trials using
autologous leukocytes chemically coupled with such peptides (11).
Indeed, tolerance induction with alpha B-crystallin (HspB5) has
been tested in patients with MS showing good safety as well (43).
In the case of NMOSD, almost 80% of patients have specific
antibodies against AQP4, providing a good target for antigen-
specific tolerance-induction strategies (12, 13). As such, the T-cell
immunogenic peptide AQP463–76 described by Zamvil and co-
workers (23) was used in this trial, because it was the only known
human disease-related epitope when we started the trial. New
AQP4 epitopes have been described (44, 45), which would be
tested in future trials.
In summary, this study shows that therapy with CNS peptide-
specific loaded tolDCs is safe in patients with MS and NMOSD
and is able to induce immune tolerance as indicated by the in-
duction of regulatory T cell, Tr1, activity.
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